No Benefit Offered By Bevacizumab For Newly Diagnosed Glioblastoma
The angiogenesis inhibitor bevacizumab failed to increase overall survival or statistically significant progression-free survival for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
Join the discussion below, or Read more at MediLexicon.
Since: Dec 05
#1 Jun 4, 2013
Avastin fails to prolong life in glioblastoma brain cancer patients?
Wow! This is blockbuster news! In one study, patients who were expected to benefit the most from Avastin based on "genetic" testing had the worst survival rates.
Bevacizumab-induced tumor calcifications can be elicited in glioblastoma microspheroid culture and represent massive calcium accumulation death (MCAD) of tumor endothelial cells
Since: Dec 05
#2 Jul 16, 2014
MCED explains why glioblastoma (the most common primary brain tumor) patients who have favorable responses to bevacizumab (Avastin) develop early calcifications in the tumor bed while glioblastoma patients with poor responses to bevacizumab do not develop calcifications.”
Add your comments below
|HPV vaccination and screening combination can d...||Oct 30||VACCINES MAIM KILL||1|
|A look at the latest on breast cancer detection...||Oct '17||MichaelLWagner||1|
|Cancer patient says Dallas surgeon operated on ...||Sep '17||mad||1|
|We could do more to fight cancer like McCain's....||Aug '17||yidfellas v USA||49|
|Top 6 BOGUS "science-based-medicine" claims fou...||Aug '17||VACCINES MAIM KILL||2|
|Can the Sunshine Vitamin Help Lymphoma Patients?||Jul '17||duh||1|
|Psychological intervention reduces fear of recu...||Jun '17||Humanspirit||1|
Find what you want!
Search Oncology Forum Now
Copyright © 2017 Topix LLC